Cabaletta Bio presents preconditioning-free clinical data and automated manufacturing data for rese-cel at ASGCT 2026

Cabaletta Bio, Inc.

Two of four pemphigus vulgaris patients at lowest PC-free dose maintained drug-free responses through 6 months.
No dose-limiting toxicities or neurotoxicity; one patient had grade 1 cytokine release syndrome.
First two autoimmune patients dosed with rese-cel manufactured on Cell Shuttle met all release specs with similar PK/PD.
Higher-dose PC-free data expected 2H26; initial SLE data at lowest dose expected 1H26 at EULAR 2026 Congress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.